Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹ Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as ...

CSU affects nearly 4 million people in Europe, with over 50% of patients remaining symptomatic despite H1-antihistamines2-4 ...

. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

Phase III program in food allergy (FA) planned for H2 2026 ...

Novartis is attending the World Economic Forum (WEF) Annual Meeting from January 19-23, 2026, in Davos, Switzerland. Under the theme A Spirit of Dialogue, the program will be structured around five ...

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing Additional Novartis medicines will be made available through direct-to-patient platforms in 2026 Company ...

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...

. *Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.

. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...